ClinicalTrials.gg
Active, not recruitingNCT05509790Updated Apr 13, 2026

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

A Phase 1 interventional study of LY3484356 in Breast Neoplasms, sponsored by Eli Lilly and Company. Active, not recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Enrollment
74th of 80
17 · median 138
Started
2022
with 3 others
Phase 1
17 of 88
3 open now
Primary completion
2024-02
later than 8 of 21 live
Registered
80th of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 74th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2022, is one of 17 in phase 1, reaches primary completion later than 8 of the 21 other live ones, and was the 80th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is a study of LY3484356 in Chinese participants with advanced breast cancer. Participants must have breast cancer that is estrogen receptor positive (ER+), HER2 negative (HER2-). The purpose of this study is to measure how much LY3484356 gets into the bloodstream and how long it takes the body to remove it. The safety and effectiveness of LY3484356 will also be studied. Participation could last up to 28 months.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Native Chinese participants must be of an acceptable age to provide
  • Have locally advanced (not amenable to curative treatment by surgery) or disease and be an appropriate candidate for experimental therapy in the judgment of the investigator, after available standard therapies have ceased to provide clinical benefit
  • Have a diagnosis of ER+, - breast cancer
  • Female participants have status due either surgical/natural menopause or ovarian suppression
  • If postmenopausal status is due to ovarian suppression, participants must have a negative serum pregnancy test and agree to use highly effective, medically approved precautions to prevent pregnancy
  • Have a performance status less than or equal to (≤)1 on the (ECOG) scale
  • Have adequate organ function
  • Must be able to swallow capsules/tablets

Exclusion criteria

Exclusion Criteria:

  • Have symptomatic central nervous system (CNS) and/or carcinomatous meningitis
  • Have a serious concomitant systemic disorder

    • (HIV) positive patients are excluded unless they are well controlled on highly active antiretroviral therapy with no evidence of deficiency syndrome-defining opportunistic infections within the last 2 years, and cluster of differentiation 4 (CD4) count greater than (>)350 cells/microliter (μL)
    • Active or C virus infection
    • Severe renal impairment, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in diarrhea
  • Have visceral crisis
  • Have a serious cardiac condition
  • Have an acute leukemia or other relevant cancers
  • Females who are pregnant or lactating
  • Known allergic reaction against any of the components of the study drug
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    LY3484356 Dose Level 1

    Administered orally.

    Drug: LY3484356

  • Experimental
    LY3484356 Dose Level 2

    Administered orally.

    Drug: LY3484356

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Plasma Concentration of LY3484356

    PK: Plasma Concentration of LY3484356

    Time frame: Time Frame: Cycle 1, Day 1 through Day 3 and Day 17 through Day 18; Cycle 2 Day 1 (Cycle 1 = 30 days, Cycle 2 = 28 days)

Secondary outcomes

  1. 2. Percentage of Participants Who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)

    ORR

    Time frame: Randomization to Disease Progression or Death from Any Cause (Estimated up to 28 months)

  2. Disease Control Rate (DCR): Percentage of Participants With a BOR of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)

    DCR

    Time frame: Randomization to Disease Progression or Death from Any Cause (Estimated up to 28 months)

  3. Progression-Free Survival (PFS)

    PFS

    Time frame: Randomization to Disease Progression or Death from Any Cause (Estimated up to 28 months)

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Feb 2024, 16 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 16 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Aug 22, 2022
StartActual
Oct 9, 2022
Primary completionActual
Feb 18, 2024
CompletionEst.
Dec 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05509790
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Oct 9, 2022
Primary completion
Feb 18, 2024
Completion
Dec 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imlunestrant

Start the discussion